Tyrosine phosphorylation of CagA could efficiently be blocked by the Src and Abl inhibitor dasatinib, and thus Src and Abl represent possible targets in the treatment of CagA-positive MALT lymphoma. Here, S100A8 is linked to MALT lymphoma.